Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Study with completed results acquired from Horizon in 2024.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of Graves' disease associated with active TED and a clinical activity score of ≥ 4
Fewer than 9 months from onset of TED
No previous medical or surgical treatment, excluding local supportive measures and oral steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent with at least 6 weeks between last administration of oral steroids and randomization
Euthyroid or with mild hypo or hyperthyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below the normal limits (every effort should be made to correct the mild hypo- or hyperthyroidism promptly)
You may not be if
Optic neuropathy
Corneal decompensation unresponsive to medical management
Oral or IV steroid treatment for any non-TED reason in the preceding 3 months
Poorly controlled diabetes
Platelets \< 100 x 10\^9/L
Hemoglobin concentration \> 2 g/dL below the lower limit of normal
Clareo Health | Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
